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Decreased expression 
of the thyroid 
hormone‑inactivating enzyme 
type 3 deiodinase is associated 
with lower survival rates in breast 
cancer
iuri Martin Goemann1, Vicente Rodrigues Marczyk1,5, Mariana Recamonde‑Mendoza2,3, 
Simone Magagnin Wajner1,5, Marcia Silveira Graudenz4,5 & Ana Luiza Maia 1,5*
thyroid hormones (tHs) are critical regulators of cellular processes, while changes in their levels 
impact all the hallmarks of cancer. Disturbed expression of type 3 deiodinase (DIO3), the main 
tH‑inactivating enzyme, occurs in several human neoplasms and has been associated with adverse 
outcomes. Here, we investigated the patterns of DIO3 expression and its prognostic significance 
in breast cancer. DIO3 expression was evaluated by immunohistochemistry in a primary cohort of 
patients with breast cancer and validated in a second cohort using RnA sequencing data from the 
TCGA database. DNA methylation data were obtained from the same database. DIO3 expression 
was present in normal and tumoral breast tissue. Low levels of DIO3 expression were associated with 
increased mortality in the primary cohort. Accordingly, low DIO3 mRnA levels were associated with 
an increased risk of death in a multivariate model in the validation cohort. DnA methylation analysis 
revealed that the DIO3 gene promoter is hypermethylated in tumors when compared to normal tissue. 
In conclusion, DIO3 is expressed in normal and tumoral breast tissue, while decreased expression 
relates to poor overall survival in breast cancer patients. Finally, loss of DIO3 expression is associated 
with hypermethylation of the gene promoter and might have therapeutic implications.
Breast cancer is the most common cancer in women worldwide, accounting for more than two million new cancer 
cases and 14.9% of all cancer-related deaths in women in  20181. Despite remarkable advances in the treatment 
of breast cancer in recent decades, not all patients benefit from current therapeutic options and thus will experi-
ence  relapse2,3. Genomic tests improve the clinical prediction of patient outcomes and determine the necessity 
of adjuvant chemotherapy with endocrine  therapy3,4. However, it is a highly heterogeneous disease that is diverse 
in its behavior and responsiveness to the different modalities of  treatment5,6. Breast cancer is characterized based 
on receptor and gene expression profiles that, together with the classic clinicopathological variables, guide the 
treatment and estimate the risk of  recurrence3,4. Gene expression profiling studies have established at least four 
molecularly distinct types of breast cancer that can be expanded to the “intrinsic” subtypes luminal A (LumA), 
luminal B (LumB), HER2-enriched, basal-like, and normal-like7–9.
Numerous studies have established thyroid hormones (THs) as critical regulators of multiple cellular processes 
in normal and tumor  cells10. They contribute to cellular proliferation and differentiation during development 
and adulthood and are fine-tuned for tissue-specific  control10,11. Clinical studies associate TH levels with breast 
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cancer risk and  mortality12,13, while in vitro models demonstrate the effect of THs on breast cancer cell prolifera-
tion, apoptosis, and  migration14–16.  T4 promotes cell proliferation through the αvβ3 integrin  receptor14, while 
the proliferative effects of  T3 depend, at least partially, on the presence of estrogen receptors in breast cancer 
 cells17,18. Clinically, however, the effects of THs on specific histopathological and molecular subtypes of breast 
cancer are still  unclear19,20.
Modulation of THs concentrations is orchestrated by a group of selenoproteins called iodothyronine deio-
dinases, which can activate and inactivate thyroid  hormones21. Briefly, the type 1 deiodinase (DIO1) catalyzes 
both activation and inactivation of thyroxine  (T4), generating triiodothyronine  (T3) and reverse triiodothyronine 
 (rT3),  respectively22. Type 2 deiodinase (DIO2) acts locally, converting the prohormone  T4 into the active  T3. 
Meanwhile, type 3 deiodinase (DIO3) is the main TH-inactivating enzyme by degrading  T4 and  T3 to inactive 
metabolites  (rT3 and diiodothyronine, respectively)21. The DIO3 gene is found in the DLK1-DIO3 genomic region, 
which is located on human chromosome  14q3223. DIO3 gene is subject to genomic imprinting, an uncommon 
epigenetic phenomenon that results in the preferential expression of one of the alleles (paternal allele in the 
case)24,25. DIO3 gene expression is increased in several tissues during embryogenesis, but it decreases in most 
tissues in  adulthood26,27. Notably, DIO3 is expressed in normal and pathological hyperproliferative conditions, 
where it has been implicated in cell proliferation and  differentiation20,25,26,28. In particular, studies have dem-
onstrated that the local control of THs signaling provided by the regulation of DIO3 activity is associated with 
cancer development, progression, and  recurrence28–30. We have previously reported that DIO3 mRNA and activity 
levels are increased in papillary thyroid cancer (PTC), which are associated with larger tumor size, and the pres-
ence of lymph node and distant metastasis at  diagnosis30. Others have described hyperexpression of this enzyme 
in basal cell carcinoma (BCC), where it modulates intracellular  T3 concentrations and thus contributes to the 
cell tumorigenic  potential31. DIO3 exerts a similar function in colon cancer, which suggests that attenuation of 
the TH signal is part of the oncogenic process, at least in some types of  cancer28.
Considering the implied role of the DIO3 gene in human neoplasms and the potential effect of TH in breast 
 carcinogenesis13–15, we investigated the expression patterns of DIO3 in normal breast tissue and breast cancer. 
Here, we demonstrate that DIO3 is expressed in normal breast tissue and breast cancer tissue. In breast cancer, 
reduced DIO3 expression is associated with decreased overall survival. Interestingly, loss of DIO3 expression 
might be explained, at least partially, by gene promoter hypermethylation.
Results
DIO3 in normal breast and fibroadenoma. DIO3 immunohistochemistry staining was detected in all 
samples of normal breast tissue (N = 5) at an overall moderate intensity (H-score = 160 ± 63). DIO3 staining 
was predominantly cytoplasmatic and more pronounced in the apical extremity in luminal cells in both ducts 
and acini of the breast (Fig. 1A). DIO3 was markedly positive in myoepithelial cells (Fig. 1A, bottom). Benign 
fibroadenoma lesions (N = 4) were also positive for DIO3 staining, with an intensity comparable to healthy tissue 
(H-score = 153 ± 41 vs. 160 ± 63, P = 0.75).
Figure 1.  Patterns of expression of DIO3 in breast samples. Immunostaining was performed as described 
in Materials and Methods. From left to right: (A) normal glandular breast tissue, (B) breast carcinoma with 
low expression (overall intensity 1+), (C) breast carcinoma with moderate expression (overall intensity 2+) 
and (D) breast cancinoma with high expression (overall intensity 3+) of DIO3 protein evaluated through 
immunohistochemistry. The staining intensity level is used to calculate the H-score, combined with the 
percentage of positive cells (see “Methods”).
3
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:13914  | https://doi.org/10.1038/s41598-020-70892-4
www.nature.com/scientificreports/
DIO3 protein in breast cancer: the primary cohort. To study DIO3 expression in breast cancer, we 
analyzed a cohort of patients who had been seen at our institution (primary cohort, N = 44) and validated the 
results in the TCGA-BRCA cohort (validation cohort, N = 1,094). The clinicopathological characteristics of the 
patients from both cohorts are summarized in Table 1.
Patterns of DIO3 staining evaluated through immunohistochemistry in breast cancer samples are shown in 
Fig. 1B–D. DIO3 staining in FFPE breast cancer tissues was positive in 35/39 (89.7%) samples of invasive ductal 
carcinoma (IDC), with a mean H-score of 104.9 ± 55. When evaluating invasive lobular carcinoma (ILC), only 1 
of 3 samples was positive for DIO3 (H-score = 86). A sample of ductal carcinoma in situ (DCIS) was also positive 
for DIO3 expression (H-score = 100). A graph comparing the H-score for DIO3 in non-malignant tissues and 
malignant breast cancer types is presented in Fig. 2A. Mean DIO3 H-scores of primary tumors were similar to 
the non-tumoral tissues, with a marginal decrease in DIO3 seen in invasive lobular carcinoma (ILC) (P = 0.05). 
Table 1.  Baseline characteristics of patients with breast cancer included in the primary cohort and in the 
validation cohort. N/A not available, IQR interquatile range, SD standard deviation, HER2 human epidermal 
growth factor receptor2, AJCC American Joint Committee on Cancer. *Classified by the AJCC 2018 staging 
system. **Classified by PAM50, data available for 513 patients.
Characteristic Primary cohort (N = 44) Validation cohort (N = 1,094)
Median age at diagnosis (range)—years 52 (26–71) 59 (26–90)
Tumor size in the largest dimension—mm
Median (IQR) 20 (13–30) N/A
Mean (± SD) 31.15 ± 29.1 N/A
Estrogen receptor—no (%)
Positive 25 (58.1%) 807 (73.7%)
Negative 18 (41.9%) 237 (21.6%)
Missing 0 50 (4.6%)
Progesterone receptor—no (%)
Positive 24 (55.8%) 698 (63.8%)
Negative 19 (44.2%) 343 (31.3%)
Missing 0 53 (4.8%)
HER2 status—no (%)
Positive 12 (27.9%) 114 (13.2%)
Negative 30 (69.8%) 649 (59%)
Missing 1 (2.3) 331 (30%)
Histological type of tumor—no (%)
Invasive Ductal Carcinoma (IDC) 40 (90.9%) 813 (79.7%)
Invasive Lobular Carcinoma (ILC) 3 (6.8%) 207 (20.3%)
Ductal Carcinoma in situ (DCIS) 1 (2.3%) 0
Clinical-pathological subtype—no (%) AJCC* 2018 PAM50**
Luminal A 8/44 (18.2%) 231 (45%)
Luminal B 17/44 (38.6%) 127 (24.7%)
HER2 7/44 (15.9%) 58 (11.3%)
Triple Negative 10/44 (22.7%) 97 (18.9%)
Non classified 2 (4.5%)
Lymph node metastasis—no (%)
Yes 17 (39%) 558 (52%)
No 26 (61%) 516 (48%)
Distant metastasis—no (%)
Yes 4 (9.3%) 14 (1.8%)
No 39 (91.7%) 768 (98.2%)
Tumor staging—no (%)
Stage I/II 30/44 (68.2%) 182 (73.2%)
Stage III/IV 12/44 (27.3%) 269 (24.6%)
Missing 2 (4.5%) 24 (2.2%)
Pre-treatment hypothyroidism—no (%) 1/43 (2.3%) N/A
Post-treatment hypothyroidism—no (%) 3/43 (7%) N/A
Follow-up (mean ± SD)—months 81.9 +—32.7 22.2 (12.9–47.5)
All-cause mortality—no (%) 11/43 (25.5%) 152/1,094 (13.9%)
Mean survival months (95% CI) 115.7 (102.2–129.2) 153.7 (136.8–170.6)
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The mean H-score of invasive ductal carcinoma was similar to that of normal tissue (P = 0.78). No differences 
were observed between the molecular subtypes of breast cancer (P = 0.8) (data not shown). There was no dif-
ference in the H-score between tumors with ER-positive and ER-negative status (P = 0.31) (Fig. 2B) or between 
tumors with HER2-positive and HER2-negative status (P = 0.81) (Fig. 2C). Among the primary tumors, there 
was no significant correlation between H-score and Ki-67(%) levels (P = 0.9), or between H-score and histologi-
cal tumor grade (P = 0.43).
We found no association of DIO3 positivity (negative or positive) with tumor size (P = 0.18). The mean 
H-score in primary tumors of patients without nodal metastases was similar to that observed in patients with 
lymph node metastasis (P = 0.07). Similarly, H-scores of primary tumors of patients with distant metastasis did 
no differ from those without distant metastasis (P = 0.78; Fig. 2D,E). There were no differences on DIO3 H-scores 
when comparing patients with stage I/II vs. stage III/IV disease (P = 0.41) (Fig. 2F). We obtained both primary 
and lymph node tissues from 5 patients. In this subset of patients, DIO3 staining was comparable between paired 
primary tumor and lymph node metastasis (P = 0.36).
Table 2 shows the variables associated with an increased risk of death in the primary cohort (univariate 
analysis). We observed that negative DIO3 staining was associated with poor prognosis (HR 4.29; 95% CI 1.24 
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Figure 2.  DIO3 staining and clinicopathological characteristics of patients with breast cancer in the primary 
cohort. (A–F) Box plots of DIO3 staining in breast tissue samples evaluated through immunohistochemistry 
and quantified by H-Score. Samples were divided according to clinicopathological data as follows: (A) type of 
tissue analyzed, (B) ER status, (C) HER2 status, (D) lymph node status, (E) distant metastasis and (F) TNM 
anatomic staging. (G) Kaplan–Meier plot of overall survival in patients with the presence (gray) or absence 
(black) of DIO3 staining in breast cancer evaluated through immunohistochemistry. ER estrogen receptor, 
HER2 human epidermal growth factor receptor2, IDC invasive ductal carcinoma, ILC invasive lobular 
carcinoma, N.S. not significant *P = 0.05.
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test. Patients with negative DIO3 staining had a worse overall survival than those with positive DIO3 staining. 
The mean overall survival was 73.3 months (95% CI 41 to 105) in the DIO3-negative group and 122 months 
(95% CI 109 to 135) in the DIO3-positive group (Fig. 2G, log-rank P = 0.012).
DIO3 mRNA in breast cancer patients: validation cohort. It has been previously demonstrated that 
DIO3 protein levels and activity correlate with DIO3 mRNA levels in different  contexts30,32,33. Therefore, to vali-
date differences of DIO3 expression among patients with breast cancer, we analyzed DIO3 mRNA expression in 
a second cohort using available gene expression data from the TCGA-BRCA study. In this second population, 
DIO3 expression was found to be reduced in primary solid tumors (N = 1,094) compared to that observed in 
normal breast samples (N = 113, logFC = -1.54, adjusted P value < 0.00001, Fig. 3A), even when the comparison 
was made only with matched normal tissues (logFC = -1.800 adjusted P value < 0.00001, Fig. 3B). The majority 
of tumor subtypes (with the exception of normal-like tumors), classified according to PAM50 classification sys-
tem, showed reduced DIO3 expression compared to normal tissue (Fig. 3C). On the other hand, DIO3 expres-
sion was increased in ER-positive samples compared to that in ER-negative samples (logFC = 0.428; P = 0.013, 
Fig. 3D). There was no significant difference when comparing DIO3 expression between patients with or without 
lymph node disease (logFC = 0.0359, adjusted P value = 0.914) or distant metastasis (logFC = -0.190, adjusted 
P value = 0.971, Fig.  3E). Decreased DIO3 mRNA expression was observed in all tumor stages compared to 
that seen in normal tissue (P < 0.01). However, no differences were found between the different tumor stages 
(Fig. 3F). Interestingly, lower DIO3 expression was associated with greater tumor size (P = 0.019) and ER nega-
tivity (P = 0.022).
We then evaluated the prognostic value of DIO3 mRNA expression for patient survival. We considered 
patients as having high DIO3 expression when their logCPM values were above the median and as having low 
DIO3 expression when their logCPM values were below the median. Low DIO3 expression was associated with 
reduced survival, with an HR of 1.60 (95% CI 1.18 to 2.26; P = 0.003) in the univariate model (Table 3). Additional 
analysis using a multivariate model adjusted for all variables with a P < 0.1 in the univariate analysis demonstrated 
that low DIO3 was an independent prognostic factor for death (HR 1.55; 95% IC 1.07 to 2.24; P = 0.02; Table 3, 
Fig. 4A). The estimated overall survival rate at five years in the Kaplan–Meier analysis was 90.4% (95% CI, 86.4% 
to 94.5%) in the high DIO3 group and 77.4% (95% CI, 71.3% to 84.1%) in the low DIO3 group (Fig. 4A).
In the subgroup analysis of patients with advanced disease (stage IV), those with low DIO3 expression had 
reduced overall survival compared to patients with high DIO3 expression (P = 0.011; Fig. 4B). Notably, low DIO3 
expression was associated with worse overall survival among patients with ER-positive tumors (P = 0.0012) but 
not among those with ER-negative tumors (P = 0.89) (Supplementary Fig. 1).
Methylation of DIO3 gene promoter. To further investigate possible factors that could lead to decreased 
DIO3 expression in breast cancer, we performed DNA methylation analysis of a subgroup of patients from 
TCGA-BRCA database from whom DNA methylation data were available (N = 890). Our analysis demonstrated 
that global DNA methylation levels of breast cancer samples were similar to those of healthy breast tissues 
(Fig. 5A). However, the methylation levels of CpG sites in the DIO3 gene region were increased compared to 
those from healthy tissue (Fig.  5B) (P < 0.0001). Figure  5 details the CpG sites that are hypermethylated (*) 
within the DIO3 gene region. The first 1.5 kbp of 5′ flanking region (red) are known to be extremely G + C rich 
(80% of the sequence), and this region is highly conserved between mouse and human  genome34. Promoter 
region (~ -250  bp of the 5′ flanking region) is composed of several promoter elements (Fig.  5C, enhanced), 
including a TATA box, two CAAT boxes and CG rich  regions35. We observed a significant increase in DNA 
methylation levels in CpG sites that are located both at the promoter region and in the 5′ flanking 1.5 kbp con-
served region of the gene (Fig. 5C,D).
Table 2.  Univariate Cox regression analysis of overall survival in breast cancer patients in the primary cohort. 
HR hazard ratio, CI confidence interval, ER estrogen receptor, P progesterone, HER2 human epidermal growth 
factor receptor2.
Variable HR (95% CI) P value
Age at diagnosis (years) 1.01 (0.95–1.06) 0.74
Tumor size (mm) 1.03 (1.01–1.04) 0.002
Lymph node metastasis (pos vs. neg) 4.71 (1.24–17.81) 0.026
Distant metastasis (pos vs. neg) 4.57 (1.17–17.77) 0.029
ER status (pos vs. neg) 0.54 (0.16.–1.79) 0.32
P status (pos vs. neg) 0.40 (0.12–1.38) 0.15
HER2 positivity (pos vs. neg) 1.80 (0.49–6.42) 0.38
TNM staging (III/IV vs I/II) 6.54 (1.83–23) 0.003
DIO3 status (neg vs. pos) 4.29 (1.24–14.7) 0.021
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Discussion
Disruption of the iodothyronine deiodinases expression leads to changes in TH concentrations, which might 
contribute to cancer development and progression by impacting virtually all the hallmarks of  cancer10. Here, 
we demonstrate that the TH-inactivating enzyme DIO3 is expressed in normal breast tissue and that its expres-
sion is highly prevalent in breast cancer. More interestingly, our results demonstrated that low DIO3 expression 
Figure 3.  The relationship between DIO3 mRNA expression and clinicopathological parameters in breast 
cancer samples of patients from the TCGA-BRCA cohort expressed in Log2 counts per million (voom-
transformed). Comparative expression demonstrates that DIO3 mRNA is decreased in tumoral tissue when 
compared to normal tissue when analyzing (A) all samples or (B) only matched samples. (C) All tumor subtypes 
have decreased expression of DIO3 mRNA when compared to normal tissue, with the exception of normal-like 
tumors compared to normal tissue. DIO3 mRNA levels were also reduced in basal-like tumors when compared 
to luminal A (**) (logFC = -1.024; adjusted P value = 0.0003) and in luminal B when compared to luminal A 
subtypes (***) (logFC = -0.915 adjusted P value = 0.0009), and (D) DIO3 expression is increased in ER-positive 
samples when compared to ER-negative samples. (E) DIO3 expression is similar in patients with or without 
metastasis. (F) When samples were separated according to tumor staging, all tumor stages had decreased DIO3 
expression when compared to normal tissue, but there was no difference in expression between the stages. ER 
estrogen receptor. *Adjusted P value < 0.0001 in comparison to normal tissue.
Table 3.  Univariate and multivariate Cox regression and for overall survival in the validation cohort. HR 
hazard ratio, CI confidence interval, ER estrogen receptor, P progesterone, HER2 human epidermal growth 
factor receptor2. *All variables with P < 0.1 were included in the multivariate model. TNM is not included as it 
is derived from variables already present in the model.
Variables
Univariate analysis Multivariate analysis*
HR (95% CI) P value HR (95% CI) P value
Age at diagnosis (years) 1.03 (1.02–1.04)  < 0.001 1.04 (1.02–1.05)  < 0.001
Tumor size (≥ 2 cm vs ≤ 2 cm) 1.48 (1.00–2.18) 0.045 1.31 (0.83–2.08) 0.25
Lymph node (pos vs. neg) 2.13 (1.49–3.05)  < 0.001 1.87 (1.24–2.81) 0.003
Distant metastasis (pos vs. neg) 4.33 (2.57–7.20)  < 0.001 2.92 (1.61–5.30)  < 0.001
E2 status (pos vs. neg) 0.71(0.48–1.00) 0.056 0.66 (0.36–1.22) 0.187
P status (pos vs. neg) 0.31 (0.52–1.02) 0.066 0.31 (0.42–1.31) 0.309
HER2 positivity (pos vs. neg) 1.43 (0.89–2.28) 0.13
TNM staging (III/IV vs I/II) 2.49 (1.78–3.48)  < 0.001
DIO3 status (low vs. high) 1.60 (1.18–2.26) 0.003 1.55 (1.07–2.24) 0.02
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was an independent prognostic factor for reduced overall survival in two different populations of patients with 
breast cancer.
Data on the expression of iodothyronine deiodinases in human breast tissue are scarce. Low levels of DIO1 
were reported in normal and lactating tissues, but DIO2 and DIO3 have not been analyzed thus  far36. Here we 
show that DIO3 is expressed at both the mRNA and protein levels in normal human breast tissue. Expression of 
DIO3 mRNA has been previously described in breast cancer cell lines (MCF-7 and MDA-MB-231 cells). DIO3 
mRNA was found to be upregulated in MCF-7 cells and down-regulated in MDA-MB-231 cells when compared 
to the non-tumoral cell line (MCF-10A cells). DIO3-mediated  T3 deiodination also occurs in MCF-7 cells. In 
these cells, DIO3 expression is to regulated by retinoids but not by  estradiol37–39. These findings are consistent 
with the presence of DIO3 in other tissues of ectodermal origin, such as the skin and the nervous  system40,41.
The role of thyroid hormone metabolism on human tumorigenesis has been largely  debated10. In breast 
cancer, previous studies showed that higher levels of the thyroid hormone receptor alpha were an independent 
prognostic factor for increased overall  survival42. More recently, high levels of the thyroid hormone receptor beta 
in breast tumors were also associated with increased breast cancer-specific  survival43.
In basal cell carcinomas (BCC), for instance, a DIO3-mediated decrease in T3 levels relates to increased 
cell  proliferation31. Similarly, in colon cancer cells, DIO3 knockdown and consequent increases in T3 levels are 
associated with reduced cell proliferation and induction of  differentiation44. High levels of DIO3 expression in 
primary PTC tumors were associated with advanced disease at the  diagnosis30. Some data indeed suggest that 
T3 can contribute to tumor growth in breast cancer cells in vitro17, while a microenvironment with low T3 levels 
could facilitate invasiveness and dedifferentiation. However, in agreement with our data in breast cancer, similar 
levels of DIO3 mRNA are observed in glioblastoma and liver carcinomas as compared to respective normal 
 tissues45. These differences could be attributed to the tissue embryological origin since the tissues of ectodermal 
origin seem to maintain DIO3 expression during adulthood, while DIO3 gene is subject to imprinting in other 
tissues. Loss of DIO3 expression was associated with tumor aggressiveness in colon cancer and also in thyroid 
cancer. DIO3 expression is present in papillary and follicular subtypes, but not in the most aggressive and dedif-
ferentiated anaplastic  subtype30. Taken together, these results indicate that, although expression of the enzyme 
is often upregulated in the neoplastic tissue compared to normal tissue, loss of DIO3 expression is a common 
hallmark of dedifferentiation in the neoplastic process, which might confer its prognostic significance. Alter-
natively, the distinct pattern of expression could be the result of DIO3 regulation or related to the cancer-type 
specific methylation signature.
Although this was an exploratory study, our results point to a prognostic role for DIO3 expression in breast 
cancer. In a primary cohort of 44 patients with breast cancer, negative DIO3 staining in the primary tumor 
was associated with significantly worse prognosis (HR 4.29; 95% CI 1.24 to 14.7; P = 0.021) when compared to 
patients who were DIO3-positive. More interesting, in the second cohort, low DIO3 expression was an inde-
pendent prognostic factor for death in a model adjusted for age, tumor size, lymph node and distant metastasis, 
estrogen and progesterone status (HR 1.55; 95% IC 1.07–2.24; P = 0.02). The prognostic role of DIO3 expression 
was particularly relevant in the subgroup of patients with advanced disease.
Intriguingly, the difference in survival between groups with distinct DIO3 expression was limited to ER-posi-
tive patients. Previous studies indicate the existence of a crosstalk between estrogen- and TH-dependent regula-
tory pathways in breast  cancer14,17,46,47, which might be a potential explanation.  T3 regulates cell cycle progression 
and proliferation in breast cancer cells in vitro by a common mechanism involving ER and  T3 receptor-mediated 
 pathways46. Moreover,  T4 can phosphorylate nuclear ER-alpha in MCF-7 cells via a MAPK-dependent pathway, 
promoting  proliferation14. Therefore, loss of DIO3 expression and the consequent increase in intracellular  T3 
levels could be specifically detrimental to tumors that express ER, as our results suggest. Contributing to this 
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Figure 4.  Kaplan–Meier estimates of overall survival in patients of the TCGA-BRCA cohort according to 
DIO3 mRNA expression. Patients were grouped according to the median of DIO3 expression in the population 
as presenting high DIO3 expression (gray lines) or low DIO3 expression (black lines). Plot A shows the 
overall survival in the entire cohort. Plot B refers only to patients with stage IV disease. HR = hazard ratio; 
CI = confidence interval.
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interplay, previous studies have demonstrated that estrogen, progesterone and their receptors regulate DIO3 
activity in rat uteri and  decidua48,49. Therefore, we cannot rule out that in the breast, DIO3 expression depends 
partially on the presence of functional estrogen and progesterone receptors.
Figure 5.  Panel (A) demonstrates mean global DNA methylation levels (β-values) in breast cancer tissue 
compared to healthy breast tissue. Panel (B) demonstrates that the mean DNA methylation of DIO3 gene region 
is increased in tumor tissue when compared to normal tissue (P < 0.001). Panel (C) is a schematic representation 
of the location of DIO3 gene in chromosome 13 and the regions that were evaluated by CpG probes. The 
promoter region is composed by several promoter elements including a TATA box, two CAAT boxes and CG 
rich regions (C, enhanced). Significant hypermethylation in several CpG sites (*) is observed in the promoter 
region of the gene. Panel (D) presents mean β-values of CpG sites mapped in DIO3 gene region comparing 
normal and tumoral tissue.
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The DIO3 gene is subject to genomic imprinting, an uncommon epigenetic phenomenon that results in the 
preferential expression of one allele (the paternal allele, in this case)24,25. The disturbed expression of genes and 
miRNAs, or altered hypermethylation patterns of the DLK1-DIO3 genomic region, is involved in the pathogen-
esis of different types of  cancer50–53. Thus, we hypothesized that the loss of DIO3 expression in breast tumors 
could be a consequence of gene hypermethylation in the tumoral context. Indeed, our results show that while 
the mean global methylation in breast tumors is comparable to that of normal tissue, the DIO3 genomic region, 
especially its promoter region, is significantly hypermethylated in tumors (Fig. 5C, enhanced). These findings 
might explain, at least in part, the reduced DIO3 expression in breast cancer. Of interest, the DIO3 gene was also 
found to be hypermethylated in B-cell, T-cell and myeloid malignancies, and lung  cancer51,52.
Our study has some limitations. The absence of data on DIO3 enzymatic activity limits the assumption that 
the decreases of DIO3 levels cause alterations in intracellular TH homeostasis. Alternatively, changes in DIO3 
expression could simply represent a consequence of broader epigenetic modifications in the tumoral context. 
It is also important to consider that complete clinical data on patient thyroid status was not available, which 
could interfere with deiodinase  expression54, 55. Therefore, the complex changes on deiodinases and the overall 
effect on intracellular TH status are still unclear in breast cancer. Additionally, our analysis is limited to two 
populations, using two different methodology, and, despite robust supporting data, results should be confirmed 
in other cohorts.
In conclusion, the results of this study demonstrate DIO3 expression in breast tissue and breast cancer. 
Importantly, low DIO3 expression is associated with reduced overall survival, suggesting that DIO3 might have 
a prognostic role in this disease. Reduced DIO3 expression in breast cancer can be explained at least in part by 
gene hypermethylation. Due to its potential to modulate thyroid hormone intracellular levels and interplay with 
estrogen metabolism in breast cancer, the DIO3 expression might have therapeutic implications.
Methods
Patients and tissues: primary cohort. Neoplastic tissue from 44 patients diagnosed with breast cancer 
was retrospectively collected from a consecutive series of unselected patients in the pathology department of 
Hospital de Clínicas de Porto Alegre. Tissue samples of the normal breast (N = 5) and fibroadenomas (N = 4) 
were also obtained. Histopathological reports containing information on tumor type, grade and immunohis-
tochemistry were retrieved; clinical data were retrospectively reviewed in medical records. Tumors were his-
tologically classified according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging 
 system56. All procedures performed in studies involving human participants were in accordance with the ethical 
standards of the institutional and/or national research committee. The study was reviewed and approved by the 
Institutional Review Board and Research Ethics Committee from the Hospital de Clínicas de Porto Alegre with 
a waiver of informed consent (Protocol number 16-0246).
Immunohistochemistry studies and DIO3 staining assessment. DIO3 protein expression was 
evaluated by immunohistochemical studies on 6-mm sections of formalin-fixed paraffin-embedded (FFPE) tis-
sue blocks from normal breast tissues, fibroadenomas, and primary breast cancers. The immunohistochemical 
technique consists of tissue deparaffinization and rehydration, antigenic recovery, inactivation of endogenous 
peroxidase and blockage of unspecific reactions. Samples were incubated overnight at a temperature of 4  °C 
with an anti-DIO3 rabbit polyclonal antibody (Abcam 102926, Cambridge, UK) at a dilution of 1:50, followed 
by subsequent incubation with a biotinylated secondary antibody, a streptavidin–HRP conjugate (LSAB; Dako, 
Carpinteria, CA, USA) and diaminobenzidine tetrahydrochloride (Kit DAB; Dako). The slides were examined 
using an Olympus BX51 microscope. The QCapture Pro software (Qimaging, Surrey, BC, Canada) was used to 
capture the images. DIO3 staining was evaluated by an experienced pathologist blinded to the molecular profile 
and TNM staging. The immunohistochemical results of DIO3 staining were assessed dichotomously (negative 
or positive) and semiquantitatively using the H-score method as described  previously57,58. The H-score combines 
the percentage of positive cells and staining intensity level (weak 1 + , moderate 2 + , strong 3 +) and is calculated 
using the following formula: [1 × (% cells 1 +) + 2 × (% cells 2 +) + 3 × (% cells 3 +)], with results ranging from 0 
to 300. Positive (epidermis and placenta, and epidermal nevus) and negative (connective and adipose tissue) 
internal controls were assessed for all the evaluated cases. Samples from the primary cohort were classified con-
cerning the presence or absence of these receptors and the level of Ki-67 expression into the following groups: 
Luminal A (LumA), luminal B (LumB), triple negative and HER2. A Ki-67 index cut point of 14% was defined 
to distinguish HER2 negative lumB from lumA  tumors59,60.
Differential gene expression and methylation analysis. For the validation cohort, RNA sequencing 
(RNA-Seq) RSEM gene expression data from The Cancer Genome Atlas (TCGA) breast cancer (BRCA) study 
were obtained from the Genomic Data Commons (GDC) Data Portal (https ://gdc-porta l.cni.nih.gov) using the 
TCGAbiolinks R/Bioconductor  package61. Raw expression signals for primary solid tumor samples (N = 1,094) 
and solid normal tissue samples (N = 113) were normalized and analyzed for differential expression of DIO3 
using the limma-voom pipeline from the limma R/Bioconductor  package62. P values were adjusted for multiple 
comparisons using the false discovery rate (FDR) procedure of Benjamini and  Hochberg63. Clinicopathological 
information for TCGA-BRCA samples was downloaded through TCGAbiolinks and the Broad GDAC Firehose 
(https ://gdac.bread insti tute.org) (merged level 1 clinical data). For tumors of the TCGA-BRCA cohort, data 
retrieved from PAM50 classification were used to define tumor subtype  classification64. Overall survival (OS) 
was estimated by the Kaplan–Meier method and compared by the log-rank test using functions provided by 
TCGABiolinks. For the methylation analysis, we used the TCGAbiolinks R/Bioconductor  package30 to obtain 
and analyze Illumina 450 K methylation and clinical data for 890 samples from the TCGA-BRCA study, includ-
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ing 97 samples from healthy tissues and 793 from primary solid tumors. Differentially methylated CpG sites for 
DIO3 were screened with the TCGAanalyze_DMR function, adopting an FDR-adjusted Wilcoxon rank-sum P 
value < 0.05 and a minimum absolute difference among group beta values (Δ beta) of 0.15.
Statistical analysis. Clinicopathological data were reported as the mean and standard deviation or the 
median with 25th and 75th percentiles for the continuous variables, and frequency and percentages were 
reported for categorical variables. Student’s t-test or chi-square tests were used to compare clinicopathological 
variables, and Student’s t-test or one-way ANOVA was used to compare H-scores between different groups. A 
Cox proportional hazard model was used to test the univariable and multivariable statistical effects of DIO3 
protein and DIO3 mRNA expression on patient survival. Time-to-event analysis was performed with overall 
survival as the primary outcome and was evaluated with log-rank analysis using Kaplan–Meier curves and both 
unadjusted and multivariable Cox regression analyses. We confirmed that the proportional hazards assumption 
was not violated in both populations by log–log plots and by the inclusion of time-dependent interaction terms 
for covariates with survival time in the models. All tests were two-tailed, and all analyses were performed using 
Statistical Package for Social Science Professional software version 20.0 (SPSS, Chicago, IL USA). A two-tailed 
P < 0.05 was considered statistically significant.
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